Cover Image
市場調查報告書

血栓性血管炎:開發中產品分析

Thromboangiitis - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 302499
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
血栓性血管炎:開發中產品分析 Thromboangiitis - Pipeline Review, H1 2014
出版日期: 2014年05月15日 內容資訊: 英文 46 Pages
簡介

所謂血栓性血管炎是指以四肢的中小動脈、靜脈、神經為對象,部位非動脈粥狀硬化的發炎性疾病。

本報告提供血栓性血管炎治療藥的開發情形調查分析,提供開發中的產品概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

血栓性血管炎概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中的產品概要

  • 後期階段的產品
  • 臨床實驗階段的產品

開發中的產品:各企業

治療藥的開發企業

  • AnGes MG, Inc.
  • Pluristem Therapeutics Inc.
  • t2cure GmbH
  • K-Stemcell Co., Ltd.
  • Hemostemix Ltd

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • beperminogene perplasmid
  • BMCs
  • Vascostem
  • PLX Cells For Cardiovascular Diseases
  • ACP-01

開發中產品的最新趨勢

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

目錄
Product Code: GMDHC5015IDB

Global Markets Direct's, 'Thromboangiitis - Pipeline Review, H1 2014', provides an overview of the Thromboangiitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thromboangiitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thromboangiitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Thromboangiitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Thromboangiitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Thromboangiitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Thromboangiitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Thromboangiitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Thromboangiitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thromboangiitis Overview
  • Therapeutics Development
    • Pipeline Products for Thromboangiitis - Overview
    • Pipeline Products for Thromboangiitis - Comparative Analysis
  • Thromboangiitis - Therapeutics under Development by Companies
  • Thromboangiitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
  • Thromboangiitis - Products under Development by Companies
  • Thromboangiitis - Companies Involved in Therapeutics Development
    • AnGes MG, Inc.
    • Pluristem Therapeutics Inc.
    • t2cure GmbH
    • K-Stemcell Co., Ltd.
    • Hemostemix Ltd
  • Thromboangiitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • beperminogene perplasmid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMCs - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vascostem - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLX Cells For Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Thromboangiitis - Recent Pipeline Updates
  • Thromboangiitis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal
      • Aug 16, 2012: Pluristem Receives Approval From Indian Ministry Of Health For Use Of PLX Cells In Phase II Trial For Treatment Of Buerger's Disease
      • Aug 25, 2011: Pluristem's PLX Cells Receives Orphan Drug Status For Treatment Of Buerger's Disease
      • Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Thromboangiitis, H1 2014
  • Number of Products under Development for Thromboangiitis - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Thromboangiitis - Pipeline by AnGes MG, Inc., H1 2014
  • Thromboangiitis - Pipeline by Pluristem Therapeutics Inc., H1 2014
  • Thromboangiitis - Pipeline by t2cure GmbH, H1 2014
  • Thromboangiitis - Pipeline by K-Stemcell Co., Ltd., H1 2014
  • Thromboangiitis - Pipeline by Hemostemix Ltd, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Thromboangiitis Therapeutics - Recent Pipeline Updates, H1 2014

List of Figures

  • Number of Products under Development for Thromboangiitis, H1 2014
  • Number of Products under Development for Thromboangiitis - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top